我国输入性利什曼病传播风险矩阵评估研究  

Transmission risk matrix assessment of imported leishmaniasis in China

作　　者：郝瑜婉 田添[1] 朱泽林 曹淳力[1] 李石柱[1] 周晓农[1] HAO Ya-wan;TIAN Tian;ZHU Ze-lin;CAO Chun-li;LI Shi-zhu;ZHOU Xiao-nong(National Instityte of Parasitic Diseases,Chinese Center for Disease Control and Preventio;WHO Collaborating Centre for Tropi-cal Disease;National Center for International Research on Tropical Diseases,Ministry of Science and Technolog;Key Laborato-ry of Parasite and Vector Biology,National Health Commission,Shanghai 200025,China)

机构地区：[1]中国疾病预防控制中心寄生虫病预防控制所、世界卫生组织热带病合作中心、科技部国家级热带病国际联合研究中心、国家卫生健康委员会寄生虫病原与媒介生物学重点实验室,上海200025

出　　处：《中国血吸虫病防治杂志》2018年第4期428-432,共5页Chinese Journal of Schistosomiasis Control

基　　金：国家自然科学基金(81101280、81660557);国家科技重大专项(2016ZX10004222-004、2012ZX10004220、2012ZX10004-201);国家重点研发计划(2016YFC1202005);上海市公共卫生三年行动计划项目(GWIV-29);China-UK Global Health Support Programme(GHSP)

摘　　要：目的构建输入性利什曼病传播风险评估体系,为评估我国输入性利什曼病的传播风险提供科学依据。方法运用专家咨询法,构建输入性利什曼病传播风险评价指标体系,应用风险矩阵评估方法评价我国输入性利什曼病的传播风险等级。结果通过专家咨询法建立了我国输入性利什曼病传播风险评价指标体系,其中风险发生可能性评价体系包括3个一级指标、13个二级指标,风险危害程度评价体系包括5个指标。经风险矩阵分析评估,目前我国输入性利什曼病传播风险等级为低风险。结论本研究首次使用矩阵分析方法进行输入性利什曼病的传播风险分析,提示我国存在输入性利什曼病传播的潜在风险。Objective To assess the risk of imported leishmaniasis in China,offering scientific evidences for leishmaniasis prevention and control. Methods The expert consultation method was used to establish a risk index system,and the risk matrix was used to evaluate the risk scales of leishmaniasis. Results This risk assessment indicator system included 3 first.grade in.dexes and 13 second.grade indexes to the aspect of risk probability. Five indexes were also included on the aspect of the risk haz.ard severity in this system. The transmission risk matrix assessment showed that the risk of imported leishmaniasis transmission in China was in low risk level. Conclusion This risk matrix assessment is applied for the transmission of imported leishmania.sis in China in the first time,indicating the potential risk of imported leishmaniasis in China.

关 键 词：输入性利什曼病 传播风险 风险矩阵 风险评估 

分 类 号：R531.6[医药卫生—内科学]